PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF...

Value in Health 2018 / 10 Vol. 21

PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

Laires, P.A., Esparteiro, J., Fonseca, A., Silva, C.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.1756
Date:
October, 2018
File:
PDF, 779 KB
english, 2018
Conversion to is in progress
Conversion to is failed